Close Menu

BOSTON – Early data on the impact of two insurance benefits programs that offer genetic testing to covered members suggests that such efforts could be a viable strategy to engage people in their care and deliver it in a more personalized fashion. 

Despite the step-up by the US Food and Drug Administration in regulatory action on pharmacogenetic testing, the success of these programs, which incorporate PGx, as well as other types of genetic health risk tests, suggests that interest in such tests is growing and access isn't being stifled as some had feared.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Antibody testing is expected to play an important role in the management of the COVID-19 pandemic. 


As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.